fiscal cliff issue tommorow could drive alot of stocks down..looking to get back in
I don't think Kynamro will get denied though because the FDA will want patients to have choices. So more likely Kynamro will get approved and come with very restrictive REMS that will still leave the bulk of the market to AEGR.
If you are out, you may want to ease back in, just in case it gives back some of the recent gains. We should be good through at least the end of February though, when the next Fiscal Cliff issue hits about the debt ceiling.